

QUIDEL CORP /DE/  
Form 8-K  
September 15, 2005

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

WASHINGTON, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE**  
**SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported): **September 15, 2005**

**QUIDEL CORPORATION**

(Exact Name of Registrant as Specified in its Charter)

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**0-10961**  
(Commission  
File Number)

**94-2573850**  
(IRS Employer  
Identification No.)

**10165 McKellar Court**  
**San Diego, California**  
(Address of Principal Executive Offices)

**92121**  
(Zip Code)

Registrant's telephone number, including area code:

**(858) 552-1100**

**Not Applicable**

(Former Name or Former Address, if Changed Since Last Report)

Edgar Filing: QUIDEL CORP /DE/ - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below):

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
  - o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
  - o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
  - o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 8.01 Other Events.**

On September 15, 2005, Quidel Corporation (the Company) issued a press release announcing the acquisition of an immunochemical fecal occult blood (iFOB) test from Alfa Scientific Designs, Inc. A copy of the Company's press release announcing the acquisition of the iFOB test is attached as Exhibit 99.1 hereto and incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

**(d) Exhibits.**

The following exhibit is filed with this current report on Form 8-K:

Exhibit Number	Description of Exhibit
99.1	Press release, dated September 15, 2005, announcing acquisition of immunochemical fecal occult blood test.



**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 15, 2005

**QUIDEL CORPORATION**

By: /s/ Michael J. Beck  
Name: Michael J. Beck  
Its: Vice President, Finance

**EXHIBIT INDEX**

<b>Exhibit Number</b>	<b>Description of Exhibit</b>
<b>99.1</b>	<b>Press release, dated September 15, 2005, announcing acquisition of immunochemical fecal occult blood test.</b>

